When the Depression Score Is High and the Cause Is Not Clear

You complete a PHQ-9 in a primary care office. You score a twelve. You are sleeping badly, your energy is gone, you can’t concentrate, your appetite has shifted, and the things that used to interest you feel far away. The score falls in the range for moderate depression, and you leave with a referral for therapy.

By the time you reach a therapist, the depression has been named. The work of assessment often begins from there, as though the naming had settled the question of cause. It has not.

What the PHQ-9 Actually Measures

The PHQ-9 is a good instrument doing exactly what it was designed to do. Its nine items correspond to the diagnostic criteria for major depression, each scored by frequency, producing a total that quantifies how heavy your symptom burden has been over the past two weeks. It is brief, validated across large populations, and useful for tracking whether that burden changes. What it measures is severity. It was never built to identify what is generating the symptoms it counts, so it records the weight without locating the source.

In practice, the total score carries most of the clinical weight. Each item is scored from zero to three by frequency, producing a range from zero to twenty-seven, and a total of ten or above is the point at which most clinicians act. The formal diagnostic algorithm asks for more than the total, including the presence of low mood or lost interest, and in a busy office it is the number that moves the decision. A total at or above ten reads as a problem requiring treatment, and that total can be assembled almost entirely from the somatic and cognitive items at the edges of the syndrome.

How a Score Reaches Ten Without Depressed Mood

That distinction matters most in the population where the instrument is applied with the most confidence. Five of the nine items describe experiences that the menopause transition produces directly. Disturbed sleep follows the fragmentation caused by vasomotor events. Low energy follows the shift in cerebral metabolism that accompanies the transition. Poor concentration follows the change in prefrontal and hippocampal function as estrogenic support becomes erratic. Appetite change follows the metabolic reorganization of midlife. Reduced interest follows the effect of fluctuating estradiol on the dopamine signaling that drives motivation. Endorsing these five items at a frequency of more than half the days produces a score of ten, the threshold that commonly prompts action, without endorsing depressed mood at all.

This is not a rare presentation reaching a specialty clinic. Women in midlife are among the most heavily screened people in medicine, and the PHQ-9 is administered routinely in primary care, at annual visits, and in gynecologic settings. The referral that follows an elevated score frequently ends in a therapist's office, which means the interpretive problem does not stay in the medical system where the screen was given. It arrives in the consulting room, already carrying a name.

Perimenopausal Depression Is Real

The complication is that perimenopausal depression is also real. Longitudinal research following women with no prior history of depression found that the odds of developing significant depressive symptoms roughly doubled during the transition compared with women who remained premenopausal, and hormonal measures in those same cohorts corroborated a contribution from the changing endocrine environment rather than from age alone. The elevation is specific to the window of hormonal change. An elevated score in midlife cannot be treated as a false alarm, because the risk is genuinely raised.

The exhaustion that registers on a depression screen has a physiology of its own, and it is worth understanding why the body shuts down under sustained load.

Three Different Clinical Pictures, One Identical Number

This is what makes the assessment demanding. A score of twelve can reflect a primary depressive episode that would have occurred at any age, a depression bound up with the hormonal transition that may respond to addressing the transition alongside the mood, or the somatic and cognitive burden of perimenopause registering on an instrument built to detect depression. These situations call for different treatment, and the number that flags each of them looks identical.

The instrument hands the clinician a number. The interpretation is the clinician's work, and it is the part that training most often leaves out. Graduate education in counseling and psychotherapy contains almost no instruction in the neuroendocrinology of the menopause transition, which means the clinician receiving your elevated score is frequently the least equipped in your care team to ask whether the transition is shaping what the score is measuring.

What a Careful Assessment Asks

Asking it requires no new instruments, only holding the transition in view alongside everything else in the history. Where are you in your cycle history, and have the intervals changed. When did the symptoms begin relative to that change. Is there vasomotor activity, and is it waking you. Did the sleep disruption precede the low mood or follow it. Is there a prior history of depression, or is this the first episode in a life that never included one. Did cognitive complaints arrive alongside the sleep loss. Has anyone measured anything, or has the whole presentation been assessed through a nine-item form.

The pattern that emerges from those questions is what carries clinical information. A depression that arrived with a change in cycles, accompanied by night waking and vasomotor activity, in someone with no prior depressive history, is a different formulation from a depression that has recurred across decades and is presenting again in midlife. The first calls for the hormonal transition to be assessed as a contributing driver before the mood is treated as the whole of the problem. The second calls for the treatment that has worked before, with the transition noted as a factor that may be compounding it.

What that assessment looks like in practice is a referral and a conversation. A presentation bound up with the transition deserves a clinician who will evaluate endocrine status against your age and the arc of your symptoms, rather than a single blood draw read against a range. Thyroid function, iron status, and sleep disturbance belong in the same evaluation, because each produces overlapping symptoms and each is treatable. None of this requires a therapist to practice outside of scope. It requires knowing what to ask, what to rule out, and when to send you back to the physician with a specific question rather than a general worry.

The answers do not settle the diagnosis. They reopen the question the score appeared to close. A first depressive episode arriving at forty-seven alongside a changing cycle, fragmented sleep, and new cognitive complaints is a different clinical picture from a recurrence of a depression that began at twenty-five, and it deserves to be evaluated as one, including a referral for physiological assessment before the mood is treated as the primary and only problem.

What Gets Missed When the Question Is Never Asked

The consequence of skipping that step is quiet and common. If your presentation is largely the somatic and cognitive signature of the transition, you are treated for a condition that was never the primary driver, and when the treatment produces a partial response you conclude that something in you is failing to improve. If you do have a perimenopausal depression, you receive care for the mood with the hormonal dimension left out of the plan. In both cases you absorb the gap as information about yourself. The physiology that would have explained the pattern is never examined, and you are left with a story in which you are the problem.

The Score Is Where the Question Begins

None of this argues against screening. Screening for depression in midlife matters precisely because the risk is elevated. The argument is narrower and more demanding. An instrument is only as good as the interpretation around it, and a score above threshold during the menopause transition is the beginning of a clinical question about the physiology you are living through.

Your score told someone that something was heavy. The work is finding out what you are carrying.

If you have been handed a diagnosis that never quite fit, or you are a clinician thinking carefully about what a screen can and cannot tell you, the physiology belongs in the conversation. Therapy that accounts for the whole system begins by asking what the body is doing before deciding what the mind is failing at.